Samalin L

Department of Psychiatry, CHU Clermont-Ferrand, University of Clermont Auvergne , CNRS, Auvergne INP, Institute Pascal (UMR 6602), Clermont-Ferrand

8 papers · ORCID

ArticleKetamine

Patient reported outcomes of MDD patients treated with esketamine nasal spray in real world practice: the French ELLIPSE study

Llorca P, Samalin L, Olié E +4

Europe PMC2026
ArticleKetamine

Real-world clinical practice, effectiveness and safety of esketamine nasal spray in major depressive disorder patients: a French prospective cohort (ELLIPSE study).

Llorca PM, Sauvaget A, Olié E +12

Europe PMC2026
ArticleKetamine

Trauma re-experiencing episodes during esketamine treatment in patients with treatment-resistant depression and comorbid PTSD: a retrospective case series.

Rothärmel M, Mekaoui L, Kazour F +21

Europe PMC2026
ArticleKetamine

Effectiveness and factors associated with esketamine response during the 4-week induction period for treatment-resistant depression: post-hoc analysis of the real-world ESKALE study.

Samalin L, Rothärmel M, Mekaoui L +6

Europe PMC2026
ArticleKetamine

Use of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression in Routine Practice: A Real-World French Study.

Samalin L, Mekaoui L, Rothärmel M +5

Europe PMC2024
ArticleKetamine

Real-world demographic and clinical profiles of patients with treatment-resistant depression initiated on esketamine nasal spray.

Samalin L, Mekaoui L, De Maricourt P +5

Europe PMC2024
ArticleKetamine

French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN) guidelines for the management of patients with partially responsive depression and treatment-resistant depression: Update 2024.

Yrondi A, Javelot H, Nobile B +7

Europe PMC2025
ArticleKetamine

The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic Review.

Boudieu L, Mennetrier M, Llorca PM +1

Europe PMC2023